 A 33 design will be utilized for this Phase 1 study. Three dose levels are planned and include: 1, 3, 10 mgkgdose. Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry. 